Current status of targeted therapies in advanced gastric cancer

Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays

(2011) Kab Choong Kim et al.   ANNALS OF SURGICAL ONCOLOGY

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

(2011) M. Moehler et al.   EUROPEAN JOURNAL OF CANCER

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

(2011) Katrine R. Schoennemann et al.   Gastric Cancer

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal growth factor receptor mutation in gastric cancer

(2011) Zhimin Liu et al.   PATHOLOGY

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

(2010) S. Rao et al.   ANNALS OF ONCOLOGY

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers

(2010) B. F. El-Rayes et al.   ANNALS OF ONCOLOGY

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study

(2010) M. Moehler et al.   ANNALS OF ONCOLOGY

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

(2010) F Lordick et al.   BRITISH JOURNAL OF CANCER

Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment

(2010) A. Russo et al.   CURRENT CANCER DRUG TARGETS

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

(2010) Yung-Jue Bang et al.   INVESTIGATIONAL NEW DRUGS

Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection

(2010) Toyomi Satoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial

(2010) Alicia F.C. Okines et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203

(2010) Weijing Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma

(2010) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

(2009) S-W Han et al.   BRITISH JOURNAL OF CANCER

Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)

(2009) C Pinto et al.   BRITISH JOURNAL OF CANCER

Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients

(2009) Sook Ryun Park et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

(2009) Chul Kim et al.   INVESTIGATIONAL NEW DRUGS

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

(2008) M A Kim et al.   HISTOPATHOLOGY